Immunotherapy, which includes ICB therapy that inhibits programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) signaling, tumor vaccines, and ACT, represents a hotspot of cancer therapy (103). This evidence concerns the gene CTLA4 and cancer.